Celecoxib

Mode Of Action	Selective COX-2 inhibitor. Inhibition of COX-2 provides the therapeutic effects of NSAIDs while that of COX-1 is responsible for gastric and renal side effects.
Drug Indication	Osteoarthritis, rheumatoid arthritis.
Precautions	Avoid in late pregnancy as it can cause premature closure of ductus arteriosus, renal and hepatic insufficiency, and asthma.
Contra-Indications	Known hypersensitivity to celecoxib, sulphonamide sensitive patients and aspirin sensitive patients.
Side Effects	GI disturbances, ataxia, thrombocytopenia, alopecia, and dermatitis.
Dosage	100mg BD or 200mg OD
Pregnancy Category	Category B3
Pregnancy Category Description	Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals show evidence of an increased occurrence of foetal damage, the significance of which is uncertain in human
Drug Category	DRUGS ACTING ON CNS
Drug Sub-Category	Non-opioid analgesics

Brand Name	Manufacturer Name	Distributor	Drug Strength	Packaging	Formulation	Formulation Strength	Price
Celcoxx	Getz Pharmaceuticals	Surgipharm Ltd	100mg	20	Capsule	per capsule	KES 332.00
Celcoxx	Getz Pharmaceuticals	Surgipharm Ltd	100mg	50	Capsule	per capsule	KES 890.00
Celcoxx	Getz Pharmaceuticals	Surgipharm Ltd	200mg	20	Capsule	per capsule	KES 648.00
Celcoxx	Getz Pharmaceuticals	Surgipharm Ltd	200mg	50	Capsule	per capsule	KES 1,733.00
Celcoxx	Getz Pharmaceuticals	Surgipharm Ltd	400mg	20	Capsule	per capsule	KES 989.00
Celebrex	Pfizer Global Pharmaceuticals	Surgipharm Ltd	200mg	10	Capsule	per capsule	KES 828.00
Cox-B	Beximco Pharma	Madawa Pharmaceuticals Ltd.	100mg	50	Capsule	per capsule	KES 929.00
Cox-B	Beximco Pharma	Madawa Pharmaceuticals Ltd.	200mg	50	Capsule	per capsule	KES 1,594.00
Lexib	Cipla Ltd.	Lords Healthcare Ltd.	200mg	30	Capsule	per capsule	KES 983.25

Note: Use the lowest effective dose for the shortest duration of time, consistent with individual patient treatment goals.

Osteoarthritis: Oral: 200 mg/day as a single dose or in divided doses twice daily

Ankylosing spondylitis: Oral: 200 mg/day as a single dose or in divided doses twice daily; if no effect after 6 weeks, may increase to 400 mg/day. If no response following 6 weeks of treatment with 400 mg/day, consider discontinuation and alternative treatment.

Acute pain or primary dysmenorrhea: Oral: Initial dose: 400 mg, followed by an additional 200 mg if needed on day 1; maintenance dose: 200 mg twice daily as needed

Canadian labeling; Recommended maximum dose for treatment of acute pain: 400 mg/day up to 7 days

Dosing adjustment in poor CYP2C9 metabolizers (eg, CYP2C9*3/*3): Consider reducing initial dose by 50%; consider alternative treatment in patients with JIA who are poor CYP2C9 metabolizers.

Note: Use the lowest effective dose for the shortest duration of time, consistent with individual patient treatment goals.

Dosing adjustment in poor CYP2C9 metabolizers (eg, CYP2C9*3/*3): Consider alternative.

Refer to adult dosing. No specific adjustment based on age is recommended. However, the AUC in elderly patients may be increased by 50% as compared to younger subjects. Initiate at the lowest recommended dose in patients weighing <50 kg.

Advanced renal disease: Use is not recommended, however, if celecoxib treatment cannot be avoided, monitor renal function closely.